Summer 2026

Data Science Co-op

Posted on 3/28/2026

Flagship Pioneering

Flagship Pioneering

501-1,000 employees

Venture capital building bioplatform companies

Compensation Overview

$25 - $40/hr

Cambridge, MA, USA

In Person

Category
Data & Analytics (1)
Required Skills
Python
PyTorch
Machine Learning

Get referred to Flagship Pioneering

See people who can refer or advise you

Requirements
  • Fluency in Python and experience implementing machine learning methods with standard tools and packages (e.g., PyTorch, JAX).
  • Readiness to deep dive into the biology/physics/chemistry of the platform companies we build
Responsibilities
  • Work with an interdisciplinary team of scientists to build models, organize data and deliver computational solutions.
  • Experiment with diverse datasets and novel techniques.
  • Communicate your work to a multi-disciplinary audience.
Desired Qualifications
  • Publications or experience in computer science, machine learning, computational chemistry/biology or a similar computational field.
  • Experience with generative models, natural language processing, graphical neural networks, reinforcement learning, or similar.
  • Familiarity with software development, including git and public cloud computing resources (e.g. AWS, GCP, Azure).

Flagship Pioneering funds and incubates life-sciences ventures by creating bioplatform companies, forming early-stage NewCos and guiding them to GrowthCos. It identifies broad scientific platforms that can generate multiple products, builds companies around these platforms, and moves them from inception to growth to assemble a multi-product portfolio. Unlike traditional investors, it creates new ventures from scratch and shepherds them through staged development, building a pipeline of category-leading biotech and life-science companies. Its goal is to develop a diverse portfolio of platform-based companies that advance human health and sustainability by delivering multiple products.

Company Size

501-1,000

Company Stage

N/A

Total Funding

$11B

Headquarters

Cambridge, Maryland

Founded

2000

Get referred to Flagship Pioneering

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Serif Biomedicines launched April 2026 with $50 million for modified DNA medicines.
  • Flagship and AWS announced April 1, 2026 collaboration to accelerate AI-native drug discovery.
  • The June 23, 2026 Lean partnership expands Flagship's global health-data and commercialization reach.

What critics are saying

  • Tessera, Alltrna, and Apriori cut staff in 2026, signaling repeated platform strain.
  • Omega Therapeutics entered bankruptcy after a February 2025 restructuring with Flagship support.
  • If flagship-built biotechs stall before clinic, Flagship becomes a financing machine, not an exit engine.

What makes Flagship Pioneering unique

  • Flagship has created more than 100 ventures and controls $14 billion since July 2024.
  • The April 1, 2026 AWS partnership gives portfolio companies cloud credits, AI, and go-to-market support.
  • Serif, Expedition, and Terion launches show repeatable company-creation velocity in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Flexible Work Hours

Company News

MedSpark
Aug 10th, 2026
AWS becomes Novo Nordisk's preferred AI partner for drug discovery.

AWS becomes Novo Nordisk's preferred AI partner for drug discovery. Novo Nordisk names AWS its preferred cloud and AI partner, opening a London hub to speed drug discovery. Published: August 10, 2026 AWS will anchor Novo Nordisk's cloud and AI strategy as the Danish pharma moves to speed new medicines to market under a pact unveiled Monday. The deal opens a co-innovation hub inside Novo's existing London facility where engineers from both sides will work on speeding up development of new medicines. Novo CEO Mike Doustdar said the collaboration is about "making AI a driver of innovation" across the Danish pharma, which focuses on serious chronic diseases. Novo gains access to Amazon Bio Discovery, a service offering AI models trained on biological datasets, plus Amazon Bedrock for building AI applications. The tools are meant to identify drug targets, design therapies and combine clinical, genomic and imaging data. Novo will also deploy Bedrock AgentCore, a managed platform for scaling AI agents, to make operations more efficient. Executives said the work is already paying off. Clinical documentation time has fallen, and 25,000 Novo employees have become more productive under the current setup. AWS CEO Matt Garman said forward deployed engineers and Novo's science teams can "compress drug discovery timelines" and process complex datasets securely. The agreement extends an existing relationship spanning Amazon Pharmacy, Amazon Ads and Amazon One Medical. AWS has signed similar life-sciences pacts this year with Flagship Pioneering and Johnson & Johnson, while Novo has separately worked with OpenAI and Denmark's first national supercomputer. Financial terms were not disclosed. The London hub is the latest in a wave of cloud-pharma AI partnerships reshaping how medicines get discovered.

PR Newswire
Aug 3rd, 2026
Flagship Pioneering appoints two executives to strengthen global expansion and investor relations

Flagship Pioneering has appointed Fidah Alsagoff as Executive Partner and Head of Global Initiatives and Maggie Sahlman as Executive Partner and Head of Fundraising and Investor Relations. The newly created roles aim to strengthen the firm's global innovation ecosystem and accelerate company growth. Alsagoff brings over 30 years of healthcare and life sciences experience. He previously served as Global Head of Life Sciences at Temasek International and held leadership positions in Singapore's healthcare sector. He will lead Flagship's global strategy, building on partnerships with organisations including A*STAR, the National University of Singapore, and the Francis Crick Institute. Sahlman has more than 20 years of institutional capital-raising experience. She previously served as Managing Director at Charlesbank Capital Partners and held senior roles at Houlihan Lokey and Advent International.

VCNewsDaily
Apr 27th, 2026
Serif Biomedicines launches with $50M from Flagship Pioneering to develop modified DNA medicines

Flagship Pioneering has launched Serif Biomedicines, a biotechnology company developing Modified DNA as a new class of medicines, with an initial commitment of $50 million. The Cambridge, Massachusetts-based startup emerges following five years of platform development. Serif Biomedicines is pioneering a novel approach to therapeutics using modified DNA technology. The company was developed within Flagship Pioneering's scientific innovation engine before its formal launch.

PR Newswire
Apr 21st, 2026
Flagship Pioneering launches Serif Biomedicines with $50M to pioneer modified DNA therapeutics

Flagship Pioneering has launched Serif Biomedicines with an initial $50 million commitment to develop Modified DNA as a new therapeutic platform. The company emerged after five years of platform development. Serif's Modified DNA technology aims to combine advantages of mRNA and gene therapy whilst addressing limitations like immunogenicity and inefficient nuclear access. The platform enables programmable, scalable, durable and redosable medicines without altering the genome. The company will present preclinical data at an upcoming scientific meeting showing tolerability in non-human primates and sustained gene expression with therapeutic effects following intravenous administration. Serif's initial programmes target rare diseases and immune programming. Founded in 2021 within Flagship Labs, Serif is led by CEO Jacob Rubens and co-founded by Noubar Afeyan, Geoffrey von Maltzahn, Eric Keen and Louisa Helms. The platform is protected by over 20 patent families.

PR Newswire
Apr 14th, 2026
Harbinger Health launches RESOLVE™ cancer detection category with $100M funding

Harbinger Health has announced RESOLVE™, a new category of blood-based multi-cancer detection tests designed to accelerate diagnosis in patients with suspected cancer. The first products are expected to launch commercially in the second half of 2026. The Cambridge-based biotech company raised $100 million in 2025, led by founder Flagship Pioneering, to support product development and its ongoing PROCARES prospective validation study. RESOLVE™ targets the diagnostic gap between symptom presentation and cancer diagnosis, which currently averages five months, during which mortality can increase by up to 8% monthly. The PROCARES study is nearing completion with over 88% of participants enrolled. It follows Harbinger's completed CORE-HH study, which demonstrated effective multi-cancer detection and high specificity in asymptomatic individuals.

INACTIVE